REG - Angle PLC - Contract announcement with Eisai Inc.

AngleAnnouncement

02/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240102:nRSB2723Ya&default-theme=true

RNS Number : 2723Y  Angle PLC  02 January 2024

 For immediate release  2 January 2024

 

ANGLE plc ("the Company")

 

CONTRACT ANNOUNCEMENT WITH LARGE PHARMA COMPANY, EISAI INC.

 

Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2
targeting antibody-drug conjugate, BB-1701

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is delighted to announce
that it has signed a contract with the global pharmaceutical company, Eisai
Inc. ("Eisai").

 

Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will
provide CTC analysis with its Portrait HER2 assay to assess breast cancer
patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II
study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701.  Success
in the pilot study offers the potential for multiple large scale follow-up
studies.

 

ANGLE's Portrait HER2 assay enables quantitative assessment of both HER2
protein expression (via IF) and HER2/neu gene amplification (via FISH) to
identify patients who could benefit from anti-HER2 ADC treatment. HER2-low
breast cancer accounts for 55% of all breast cancer cases with analysts
predicting that the global HER2+ breast cancer ADC market will reach US $3.3
billion per annum by 2030. Because of market expansion into HER2-low patients,
ANGLE has developed a quantitative HER2 assay to enable accurate
stratification of patient populations throughout the treatment pathway given
HER2 status can change over time.

 

ANGLE Chief Executive Officer, Andrew Newland, commented:

"The use of CTC biomarkers in clinical trials is a rapidly growing field
enabling longitudinal monitoring of genomic, transcriptomic and proteomic
changes. ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in
patients where a tissue biopsy at the metastatic site either fails or is not
feasible. We are delighted that Eisai is utilising our new HER2 assay for this
study and believe that a successful pilot study will lead the way to major
expansion of this line of our business going forward."

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Joint Broker)      +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories.  Services include custom made assay development
and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBCGDBDGGDGSB